DK1141014T3 - Insulinlignende vækstfaktor (IGF) i mutantvariant - Google Patents
Insulinlignende vækstfaktor (IGF) i mutantvariantInfo
- Publication number
- DK1141014T3 DK1141014T3 DK00901397T DK00901397T DK1141014T3 DK 1141014 T3 DK1141014 T3 DK 1141014T3 DK 00901397 T DK00901397 T DK 00901397T DK 00901397 T DK00901397 T DK 00901397T DK 1141014 T3 DK1141014 T3 DK 1141014T3
- Authority
- DK
- Denmark
- Prior art keywords
- igf
- insulin
- growth factor
- mutant variant
- mutant
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 4
- 102000013275 Somatomedins Human genes 0.000 title 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11501099P | 1999-01-06 | 1999-01-06 | |
| US17026199P | 1999-12-09 | 1999-12-09 | |
| EP00901397A EP1141014B1 (en) | 1999-01-06 | 2000-01-05 | Insulin-like growth factor (igf) i mutant variant |
| PCT/US2000/000199 WO2000040613A1 (en) | 1999-01-06 | 2000-01-05 | Insulin-like growth factor (igf) i mutant variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1141014T3 true DK1141014T3 (da) | 2005-04-11 |
Family
ID=26812755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00901397T DK1141014T3 (da) | 1999-01-06 | 2000-01-05 | Insulinlignende vækstfaktor (IGF) i mutantvariant |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6403764B1 (da) |
| EP (1) | EP1141014B1 (da) |
| JP (2) | JP3971108B2 (da) |
| AT (1) | ATE284415T1 (da) |
| AU (1) | AU762351B2 (da) |
| CA (1) | CA2356109C (da) |
| DE (1) | DE60016560T2 (da) |
| DK (1) | DK1141014T3 (da) |
| ES (1) | ES2234560T3 (da) |
| IL (2) | IL143866A0 (da) |
| PT (1) | PT1141014E (da) |
| WO (1) | WO2000040613A1 (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
| US7173005B2 (en) * | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
| PT1141014E (pt) | 1999-01-06 | 2005-04-29 | Genentech Inc | Variante mutante do factor de crescimento semelhante a insulina (igf-i) |
| US7250950B2 (en) * | 2001-01-29 | 2007-07-31 | Symyx Technologies, Inc. | Systems, methods and computer program products for determining parameters for chemical synthesis |
| US20020143725A1 (en) * | 2001-01-29 | 2002-10-03 | Smith Robin Young | Systems, methods and computer program products for determining parameters for chemical synthesis and for supplying the reagents, equipment and/or chemicals synthesized thereby |
| US6849718B2 (en) * | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US20040048925A1 (en) * | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| ES2408704T3 (es) | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
| DK2241575T3 (da) | 2005-01-07 | 2015-08-24 | Regeneron Pharma | IGF-1-fusionspolypeptider og terapeutiske anvendelser deraf |
| TWI406870B (zh) | 2005-02-21 | 2013-09-01 | Chugai Pharmaceutical Co Ltd | A method of making a protein using hamster IGF-1 |
| CL2007001614A1 (es) * | 2006-06-09 | 2008-08-08 | Novartis Ag | Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| AU2007291501B2 (en) * | 2006-08-31 | 2012-07-12 | F. Hoffmann-La Roche Ag | Method for the production of insulin-like growth factor-I |
| JP2010517023A (ja) | 2007-01-25 | 2010-05-20 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全の評価におけるｉｇｆｂｐ−７の使用 |
| US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
| JP2010529128A (ja) * | 2007-06-08 | 2010-08-26 | マサチューセッツ インスティテュート オブ テクノロジー | レット症候群および他の障害の処置 |
| MX2010010495A (es) * | 2008-04-03 | 2010-10-15 | Hoffmann La Roche | Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares. |
| EP2274624B1 (en) * | 2008-04-03 | 2011-11-09 | F. Hoffmann-La Roche AG | Pegylated insulin-like-growth-factor assay |
| PL219335B1 (pl) * | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| CA2768621C (en) | 2009-07-22 | 2016-04-05 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 |
| EP2475678B1 (en) | 2009-09-10 | 2014-10-08 | Lonza Biologics Plc. | Method and system for polypeptide purification |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| SG10201505217WA (en) | 2010-07-09 | 2015-08-28 | Biogen Hemophilia Inc | Chimeric clotting factors |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| MX350378B (es) | 2012-01-10 | 2017-09-05 | Biogen Ma Inc | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. |
| JP6499080B2 (ja) | 2012-12-18 | 2019-04-10 | ノバルティス アーゲー | 安定化されたインスリン様成長因子ポリペプチド |
| AR095527A1 (es) | 2013-03-15 | 2015-10-21 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix |
| CN104293766A (zh) * | 2013-07-15 | 2015-01-21 | 四川农业大学 | 山羊IGFBP3基因cDNA编码序列克隆的方法 |
| US20160271265A1 (en) | 2013-10-02 | 2016-09-22 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
| EP3098235A4 (en) | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
| US20170248609A1 (en) | 2014-01-27 | 2017-08-31 | Novartis Ag | Biomarkers predictive of muscle atrophy, method and use |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| AU2016215155A1 (en) | 2015-02-04 | 2017-08-17 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| EP3254104B1 (en) | 2015-02-04 | 2021-08-25 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| RU2764197C1 (ru) | 2016-09-23 | 2022-01-14 | Ханми Фарм. Ко., Лтд. | Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение |
| AR111341A1 (es) | 2017-03-23 | 2019-07-03 | Hanmi Pharm Ind Co Ltd | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo |
| CN117384275B (zh) * | 2023-12-13 | 2024-03-15 | 北京科为博生物科技有限公司 | 胰岛素样生长因子突变体igf1m及其应用 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4411890A (en) * | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US3721252A (en) * | 1971-04-01 | 1973-03-20 | Catheter And Instr Corp | Spring guide washer |
| US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
| JPH0720993B2 (ja) | 1985-08-22 | 1995-03-08 | グロペップ プロプライエタリー リミテッド | 生長因子 |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
| AU627423B2 (en) | 1987-04-06 | 1992-08-27 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them |
| ES2007309T3 (es) | 1987-04-23 | 1994-11-01 | Monsanto Co | Secrecion del factor de crecimiento insulinoide 1 en e.coli. |
| SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US4876242A (en) * | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
| US5470828A (en) | 1987-12-24 | 1995-11-28 | Gropep Pty. Ltd. | Peptide analogs of insulin-like growth factor II |
| US5164370A (en) | 1987-12-24 | 1992-11-17 | Gropep Pty. Ltd. | Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) |
| US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
| ATE86496T1 (de) | 1988-02-05 | 1993-03-15 | Ciba Geigy Ag | Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten. |
| DK131988A (da) | 1988-03-11 | 1989-09-12 | Erasmus University | Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur |
| US5258287A (en) | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
| AU1955388A (en) | 1988-04-12 | 1989-11-03 | Synergen, Inc. | Method for potentiating and inhibiting insulin-like growth factor activity |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
| CA2007886A1 (en) | 1989-01-17 | 1990-07-17 | Marvin L. Bayne | Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| GB8920381D0 (en) | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
| ZA9010332B (en) | 1989-12-22 | 1991-08-28 | Ciba Geigy | Method of reducing or preventing adverse effect of steroid therapy and compositions therefor |
| NZ236618A (en) | 1990-01-03 | 1997-06-24 | Ciba Geigy Ag | Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound |
| US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| US5593844A (en) * | 1990-11-19 | 1997-01-14 | Genentech, Inc. | Ligand-mediated immunofunctional hormone binding protein assay method |
| US5210017A (en) * | 1990-11-19 | 1993-05-11 | Genentech, Inc. | Ligand-mediated immunofunctional hormone binding protein assay method |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
| US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
| DE69218948T2 (de) | 1991-08-01 | 1997-07-31 | Auckland Uniservices Ltd | IGF-I zur Verbesserung der neuronale Lage |
| US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
| TW267102B (da) | 1992-03-13 | 1996-01-01 | Ciba Geigy | |
| SE9201573D0 (sv) * | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
| ES2140463T3 (es) | 1992-06-12 | 2000-03-01 | Cephalon Inc | Prevencion y tratamiento de la neuropatia periferica. |
| GB9217696D0 (en) | 1992-08-20 | 1992-09-30 | Agricultural & Food Res | Use of specific binding molecules |
| US5273961A (en) | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| US5342763A (en) * | 1992-11-23 | 1994-08-30 | Genentech, Inc. | Method for producing polypeptide via bacterial fermentation |
| DK0600372T3 (da) * | 1992-12-02 | 1997-08-11 | Hoechst Ag | Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer. |
| WO1994016722A1 (en) | 1993-01-25 | 1994-08-04 | The Beth Israel Hospital Association | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties |
| CA2154078A1 (en) | 1993-01-29 | 1994-08-04 | George N. Cox | Wound healing composition |
| US5457109A (en) | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| HU224345B1 (hu) | 1993-12-23 | 2005-08-29 | Novo Nordisk A/S. | Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk |
| JP3759748B2 (ja) | 1993-12-23 | 2006-03-29 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン放出性を有する化合物 |
| US5597700A (en) | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
| US5444047A (en) * | 1994-06-16 | 1995-08-22 | Dipasquale; Gene | Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I |
| SE9402331D0 (sv) | 1994-07-01 | 1994-07-01 | Pharmacia Ab | New use |
| SE9402370D0 (sv) | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
| HRP940432B1 (en) | 1994-08-05 | 2003-10-31 | Pliva Pharm & Chem Works | Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin |
| US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
| US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| SE9501472D0 (sv) | 1995-04-21 | 1995-04-21 | Pharmacia Ab | Truncated IGF-I |
| US5622932A (en) | 1995-05-05 | 1997-04-22 | Eli Lilly And Company | IGF-1 superagonists |
| US5565428A (en) | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
| US5741776A (en) | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| JP3576170B2 (ja) | 1995-05-26 | 2004-10-13 | セラテクノロジーズ・インコーポレーテッド | 生物学的活性が増加したキメラ脂肪体プロｇｒｆ類似体 |
| TR199701526T1 (xx) | 1995-06-07 | 1998-03-21 | Glaxo Group Limited | Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler. |
| WO1996040189A1 (en) | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
| EP0854884A1 (en) | 1996-04-17 | 1998-07-29 | Neurocrine Biosciences, Inc. | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
| CA2265972A1 (en) | 1996-09-16 | 1998-03-26 | Philip D. Acott | Use of igf-i for the treatment of polycystic kidney disease and related indications |
| EP0938497B1 (en) | 1996-11-06 | 2007-02-28 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| EP0965596A1 (en) | 1996-12-27 | 1999-12-22 | Daiichi Pharmaceutical Co., Ltd. | Method for elevating the concentration of free insulin-like growth factor |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
| DE19757250A1 (de) | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
| AU3548999A (en) | 1998-04-03 | 1999-10-25 | Chiron Corporation | Use of igfi for treating articular cartilage disorders |
| WO2000020023A2 (en) | 1998-10-02 | 2000-04-13 | Celtrix Pharmaceuticals, Inc. | Null igf for the treatment of cancer |
| AU6515499A (en) | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
| PT1141014E (pt) * | 1999-01-06 | 2005-04-29 | Genentech Inc | Variante mutante do factor de crescimento semelhante a insulina (igf-i) |
| JP2002535967A (ja) * | 1999-01-06 | 2002-10-29 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子（ｉｇｆ）ｉ変異体 |
| WO2000069901A2 (en) | 1999-05-19 | 2000-11-23 | Xencor, Inc. | Proteins with insulin-like activity useful in the treatment of diabetes |
| JP2009542719A (ja) | 2006-07-06 | 2009-12-03 | モレキュラー ロジックス，インコーポレイテッド | インスリン様成長因子−ｉレセプターアンタゴニスト |
-
2000
- 2000-01-05 PT PT00901397T patent/PT1141014E/pt unknown
- 2000-01-05 WO PCT/US2000/000199 patent/WO2000040613A1/en not_active Ceased
- 2000-01-05 AT AT00901397T patent/ATE284415T1/de active
- 2000-01-05 US US09/477,924 patent/US6403764B1/en not_active Expired - Lifetime
- 2000-01-05 IL IL14386600A patent/IL143866A0/xx unknown
- 2000-01-05 EP EP00901397A patent/EP1141014B1/en not_active Expired - Lifetime
- 2000-01-05 JP JP2000592321A patent/JP3971108B2/ja not_active Expired - Lifetime
- 2000-01-05 DE DE60016560T patent/DE60016560T2/de not_active Expired - Lifetime
- 2000-01-05 DK DK00901397T patent/DK1141014T3/da active
- 2000-01-05 AU AU22245/00A patent/AU762351B2/en not_active Expired
- 2000-01-05 CA CA002356109A patent/CA2356109C/en not_active Expired - Lifetime
- 2000-01-05 ES ES00901397T patent/ES2234560T3/es not_active Expired - Lifetime
-
2001
- 2001-06-20 IL IL143866A patent/IL143866A/en not_active IP Right Cessation
- 2001-12-19 US US10/028,410 patent/US7105167B2/en not_active Expired - Lifetime
-
2006
- 2006-06-21 JP JP2006171517A patent/JP2006328074A/ja active Pending
- 2006-08-28 US US11/512,046 patent/US8097587B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60016560D1 (de) | 2005-01-13 |
| US6403764B1 (en) | 2002-06-11 |
| DE60016560T2 (de) | 2005-12-15 |
| JP2006328074A (ja) | 2006-12-07 |
| EP1141014A1 (en) | 2001-10-10 |
| IL143866A (en) | 2009-11-18 |
| AU2224500A (en) | 2000-07-24 |
| JP3971108B2 (ja) | 2007-09-05 |
| EP1141014B1 (en) | 2004-12-08 |
| US8097587B2 (en) | 2012-01-17 |
| ATE284415T1 (de) | 2004-12-15 |
| US7105167B2 (en) | 2006-09-12 |
| ES2234560T3 (es) | 2005-07-01 |
| WO2000040613A1 (en) | 2000-07-13 |
| AU762351B2 (en) | 2003-06-26 |
| PT1141014E (pt) | 2005-04-29 |
| IL143866A0 (en) | 2002-04-21 |
| JP2002535968A (ja) | 2002-10-29 |
| CA2356109C (en) | 2008-04-22 |
| US20110003746A1 (en) | 2011-01-06 |
| CA2356109A1 (en) | 2000-07-13 |
| US20020160955A1 (en) | 2002-10-31 |
| WO2000040613A9 (en) | 2001-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1141014T3 (da) | Insulinlignende vækstfaktor (IGF) i mutantvariant | |
| DE69434817D1 (de) | Protease varianten | |
| DK1141015T3 (da) | Insulin-lignende vækstfaktor (IGF) I-mutantvarianter | |
| AUPP051497A0 (en) | Antimicrobial peptides | |
| BR9811187A (pt) | Composições detergentes compreendendo uma mananase e uma protease | |
| PL349468A1 (en) | Analogues of glp-1 | |
| IL143481A0 (en) | Glp-1 analogues | |
| MX9605357A (es) | Variantes de subtilisina bpn' que tiene absorcion reducida e hidrolisis incrementada. | |
| MX353234B (es) | Variantes de polipeptidos con función efectora alterada. | |
| AU2373400A (en) | Shelf-stable formulation of glucagon-like peptide-1 | |
| NO20025893D0 (no) | Veksthormon sekretagoga | |
| ZA992447B (en) | Quinoxalinones as serine protease inhibitors. | |
| MXPA02012203A (es) | Analogos de peptido 1 tipo glucagon. | |
| DK1653989T3 (da) | Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel | |
| BR9407502A (pt) | Variantes subtilisina bpn com adsorção diminuída e hidrólise aumentada | |
| ZA992448B (en) | Quinoxalinones as serine protease inhibitors. | |
| EP1273299A4 (en) | PREPARATION CONTAINING MINOXIDIL | |
| UA50808C2 (uk) | Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених | |
| LT99131A (en) | Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity | |
| ES2180948T3 (es) | Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal. | |
| ATE210149T1 (de) | Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden | |
| ID28463A (id) | KOMPOSISI DENGAN KEMURNIAN TINGGI YANG TERDIRI DARI (7α, 17α)-17-HIDROKSI-7-METIL-19-NOR-17-PREGN-5(10)-EN-20-IN-3-ON | |
| NO971508L (no) | Analoger av sur fibroblastvekstfaktor med forökt stabilitet og biologisk aktivitet | |
| PL351140A1 (en) | Lyophilisates with improved reconstitutibility | |
| AU3494093A (en) | S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents |